BioCentury
ARTICLE | Emerging Company Profile

Next, after T cells

NextCure is exploiting myeloid targets to enhance other immunotherapies

January 11, 2018 6:36 PM UTC

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T cell-targeted compounds and extend their uses to non-responders or patients who develop resistance.

The company raised $67 million in series A funding in 2016, and expects to submit an IND on its first candidate in the third quarter and start a Phase I trial by year-end. ...